36770-005.dng

A new drug based on University of Georgia research that targets inflammation and brain damage caused by strokes will soon enter clinical trials.

 Peter Frey/UGA

ATHENS — A new drug based on University of Georgia research that targets inflammation and brain damage caused by strokes will soon enter clinical trials.

Set to begin in the first half of 2024, the therapeutic drug is the first cell therapy cleared by the FDA to be used in the nervous system. It works by cleaning up the damaging particles released during and after a stroke.

0
0
0
0
0